trial

How Can a Driving Virtual Reality Tool Improve Quality of Life and Social Autonomy in Patients With Schizophrenia

NCTId NCT03973853
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Withdrawn
Enrollment 0 (actual)
Sponsored by Hôpital le Vinatier
Primary completion 2019-12-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2019-06-25
Primary completion
2019-12-30
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Virtual reality driving stimulation programTAU

Sponsors

Hôpital le VinatierLead Sponsor

Investigators

1
ROMAIN REY, PHPrincipal Investigator

Sites

2 total
Bron, FranceBron, France

Facts & assertions

4 sourced
Enrollment
0
Phase
NA
Primary Completion Date
2019-12-30
Status
WITHDRAWN
relationships
The graph out of here
drug
Virtual reality driving stimulation program
drug
TAU
drug
lead_sponsor
Hôpital le Vinatier
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
ROMAIN REY, PH
person